Person: GÜNEŞ, BEGÜM
Now showing 1 - 7 of 7
- PublicationOpen AccessRetention and survival rate of etanercept in psoriasis over 15 years and patient outcomes during the COVID-19 pandemic: The real-world experience of a single center(2020-12-01T00:00:00Z) GÜNEŞ, BEGÜM; ONSUN, Nahide; YABACI, AYŞEGÜL; ONSUN, NAHIDE; GÜNEŞ, BEGÜM; YABACI TAK, AYŞEGÜLThere have been a number of investigations of the efficacy and safety of etanercept. This study was performed to obtain long-term drug survival data (ie, time to drug discontinuation) for etanercept, and the reasons for its discontinuation. The study population consisted of patients with psoriatic arthritis and psoriasis followed up by our clinic, registered in the Turkish Psoriasis Registry (PSR-TR) and treated with etanercept for at least 4 weeks between January 1, 2005, and January 31, 2020. The efficacy of etanercept was evaluated in terms of the Psoriasis Area and Severity Index (PASI) 75, PASI 90 and PASI 100 response rates at 12, 24, 36, and 48 weeks, and annually thereafter. The behaviors of the patients with respect to the use of etanercept, and the outcomes of those who continued to use it during the COVID-19 pandemic, were also investigated.
- PublicationOpen AccessA generalized pustular psoriasis flare after CoronaVac COVID-19 vaccination: Case report(2021-01-01T00:00:00Z) ONSUN, Nahide; KAYA, GÖKHAN; IŞIK, BENGİSU GÜÇKAN; GÜNEŞ, BEGÜM; ONSUN, NAHIDE; KAYA, GÖKHAN; IŞIK, BENGİSU GÜÇKAN; GÜNEŞ, BEGÜMCoronoVac is a non-viable vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Nowadays, there has been vaccination program for at-risk groups and older adults in Turkey. We here present 72-year-old male psoriasis patient who developed generalized pustular psoriasis flare after administration of CoronoVac. The COVID-PCR test was negative and investigations for flare etiology were all normal. He was first (to the best of our knowledge) psoriasis patient who developed an erythrodermic flare after the first dose of CoronaVac vaccine.
- PublicationOpen AccessWhich dermatology patients attend to Dermatology Outpatient Clinics during the SARS-CoV-2 outbreak in Turkey and what happened to them?(2020-05-11T04:00:00Z) CENGİZ, Fatma Pelin; EMİROĞLU, Nazan; BAHALI, ANIL GÜLSEL; DİZMAN, DİDEM; TAŞLIDERE, NAZAN; MERT, Ömer; Akarslan, Tahsin Cagdas; Gunes, Begum; KÜÇÜK, Özlem Su; ONSUN, Nahide; CENGİZ, FATMA PELIN; EMİROĞLU, NAZAN; BAHALI, ANIL GÜLSEL; DİZMAN, DİDEM; TAŞLIDERE, NAZAN; GÜNEŞ, BEGÜM; MERT, ÖMER; SU KÜÇÜK, ÖZLEM; ONSUN, NAHIDECoronavirus disease, first emerged in Wuhan, rapidly spread all over the world since December 2019. There are concerns about elective dermatology appointments and its results. Herein, we aimed to find out which type of dermatologic patients attended to dermatology outpatient clinic. The patients visiting the clinics for elective dermatologic diseases between March 11 and 18, 2020, were included in this study. Their age, sex, diagnosis of disease, requirement for emergent intervention, and their medical records about COVID-19 were obtained. There were 390 patients attending to the dermatology outpatient clinic in this period. The most common disease was acne (N: 94, 24%), only 19% of patients need emergent interventions or dose adjustment. There were 40 (10%) patients over the age of 65. After their visits, five patients were diagnosed as COVID-19 in 2weeks. Dermatologic examinations may be a vector for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission since being closed to the patient. Five of our patients were diagnosed as COVID-19 after their elective visit to hospital. Since the asymptomatic course of some young patients, most of our patients were not screened for COVID-19. Our findings support the concerns of elective physician examinations.
- PublicationMetadata onlyBezmialem Vakıf Üniversitesi’nin 15 yıllık etanercept deneyimi ve etanercept sürdürülebilirliği(2020-12-04T00:00:00Z) Onsun, Nahide; Güneş, Begüm; Yabacı, Ayşegül; ONSUN, NAHIDE; GÜNEŞ, BEGÜM; YABACI TAK, AYŞEGÜL
- PublicationMetadata onlyDemographic characteristics, treatment, and outcome of patients with Kaposi sarcoma: Ten-year follow-up results of a single center(2021-09-01T00:00:00Z) GÜNEŞ, BEGÜM; MERT, Ömer; ONSUN, Nahide; GÜNEŞ, BEGÜM; MERT, ÖMER; ONSUN, NAHIDEBackground Clinical features, types of Kaposi sarcoma, and treatment outcomes have not been well-defined in Turkey. In this study, we reviewed records of the patients who had been diagnosed with Kaposi sarcoma in the last decade in a single center and evaluated treatment results. Methods Medical records of the Kaposi sarcoma patients seen in the last decade in a single tertiary center were evaluated in detail. Results A total of 27 patients were identified; 18 patients had been checked for HHV8; and 16 of those patients were positive for HHV8. One patient was positive for HIV. Two patients having mycosis fungoides and myasthenia graves developed iatrogenic KS after immunosuppressive treatments. Interferon alpha was used in 21 patients; 8 patients achieved complete response; and 11 patients achieved a partial response. No serious side effects were observed. Systemic involvement did not develop in any patients except lymph node involvement in a patient with widespread skin lesions.
- PublicationOpen AccessRetention and survival rate of etanercept in psoriasis over 15 years and patient outcomes during the COVID‐19 pandemic: The real‐world experience of a single centre(2020-12-01T00:00:00Z) Onsun, Nahide; Yabanci, Aysegul; GÜNEŞ, BEGÜMThere have been a number of investigations of the efficacy and safety of etanercept. This study was performed to obtain long‐term drug survival data (i.e. time to drug discontinuation) for etanercept, and the reasons for its discontinuation. The study population consisted of patients with psoriatic arthritis and psoriasis followed up by our clinic, registered in the Turkish Psoriasis Registry (PSR‐TR) and treated with etanercept for at least 4 weeks between January 1, 2005, and January 31, 2020. The efficacy of etanercept was evaluated in terms of the Psoriasis Area and Severity Index (PASI) 75, PASI 90 and PASI 100 response rates at 12, 24, 36 and 48 weeks, and annually thereafter. The behaviours of the patients with respect to the use of etanercept, and the outcomes of those who continued to use it during the COVID‐19 pandemic, were also investigated.
- PublicationMetadata onlyA multicentre prospective analysis of the incidence of pemphigoid diseases in Turkey(2021-10-01T00:00:00Z) DURDU, MURAT; Bozca, Burcin Cansu; ENLİ, SERVİNAZ; Yazici Ozgen, Zuleyha; YAYLI, SAVAŞ; AKTAN, ŞEBNEM; MUTLU, DERYA; ERTURAN, İjlal; AYVAZ ÇELİK, Havva Hilal; MELİKOĞLU, Mehmet; PALA, Erdal; Gursel Urun, Yildiz; HARMAN, MEHMET; BOZKURT ŞAVK, EKİN; Isik, Selin; Duygulu, Seniz; Imren, Isil Gogem; FETTAHLIOĞLU KARAMAN, BİLGE; KAYA ERDOĞAN, HİLAL; KILIÇ, ARZU; Ozcelik, Sinan; Inan, Kiymet; Yilmaz, Mustafa Anil; Sanli, Hatice Erdi; Kalay Yildizhan, Incilay; MÜLAYİM, MEHMET KAMİL; Cicek, Demet; Demir, Betul; YASAK GÜNER, RUKİYE; BAYKAL SELÇUK, LEYLA; GÜNDÜZ, KAMER; DAYE, MUNİSE; BORLU, MURAT; ÖKSÜM SOLAK, EDA; DİZMAN, DİDEM; GÜNEŞ, BEGÜM; Ozkur, Ezgi; Polat, Mualla; Eskiocak, Ali Haydar; UZUN, SONER; DİZMAN, DİDEM; GÜNEŞ, BEGÜMBackground The differentiation between the pemphigoid diseases is essential for treatment and prognosis. In Turkey, data on the incidence of these diseases are insufficient. Our aim in this study is to determine the incidence, demographics and clinical characteristics associated with diseases of the pemphigoid group. Methods We prospectively analysed 295 patients with pemphigoid who visited dermatology clinics of tertiary referral hospitals in 12 different regions of Turkey within a year. The diagnosis was based on clinical, histopathological, direct immunofluorescence (DIF) and serological (multivariant enzyme-linked immunosorbent assay [ELISA], indirect immunofluorescence and mosaic-based BIOCHIP) examinations. Clinical and demographic findings, aetiological factors and concomitant diseases observed in the patients were recorded. Results A total of 295 (female/male ratio: 1.7/1) patients with pemphigoid were diagnosed in 1-year period. The overall incidence rate of pemphigoid diseases was found to be 3.55 cases per million-years. The ratio of pemphigoid group diseases to pemphigus group diseases was 1.6. The most common pemphigoid type was bullous pemphigoid (BP, 93.2%). The others were epidermolysis bullosa acquisita (3.1%), pemphigoid gestationis (2.4%), linear IgA disease (1%) and mucous membrane pemphigoid (0.3%). The most common (26.8%) possible trigger of the bullous pemphigoid was gliptin derivative drugs. The most common concomitant diseases with pemphigoid were cardiovascular (27.8%) and neurological diseases (23.7%). Conclusions This study showed that the increased frequency of bullous pemphigoid reversed the pemphigoid/pemphigus ratio in Turkey. Further studies are warranted regarding the reasons for this increase.